Patents by Inventor Josef Vágner
Josef Vágner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952379Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to a new class of small-molecules having a pyrazino-pyrimidine-dione (or related) structure which function as modulators (activators, inhibitors) of protease activated receptor type 2 (PAR2), and their use as therapeutics for the treatment of conditions involving PAR2 activity (e.g., asthma, chronic pain, cancer and/or vascular disorders).Type: GrantFiled: April 9, 2019Date of Patent: April 9, 2024Assignees: Arizona Board of Regents on Behalf of the University of Arizona, Board of Regents, The University of Texas SystemInventors: Scott A. Boitano, Josef Vagner, Theodore J. Price, Greg Dussor
-
Publication number: 20230167154Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: January 24, 2022Publication date: June 1, 2023Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
-
Publication number: 20230135877Abstract: Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are surfactant protein-A (SP-A) peptide analogies (e.g., SP-A peptidomimetics) and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).Type: ApplicationFiled: April 8, 2021Publication date: May 4, 2023Inventors: Julie Ledford, Monica Kraft, Josef Vagner, Scott Boitano
-
Patent number: 11458212Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 9, 2019Date of Patent: October 4, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of the University of /ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20220274991Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a pyrimido-pyrimidine-dione (or similar) strucure which function as inhibitors of the Ku70/80 protein and the non-homologous end joining (NHEJ) pathway, and their use as therapeutics for the treatment of cancer and other diseases (e.g., treating subjects having conditions involving an aberrant, overexpressed or upregulated Ku70/80 profile, or subjects having conditions which canbe ameliorated by diminishing Ku70/80-mediated DSB repair).Type: ApplicationFiled: July 16, 2020Publication date: September 1, 2022Inventors: Eric Weterings, Daruka Mahadevan, Josef Vagner
-
Patent number: 11414455Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: October 5, 2020Date of Patent: August 16, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDAInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Patent number: 11351264Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.Type: GrantFiled: March 31, 2017Date of Patent: June 7, 2022Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Scott A. Boitano, Josef Vagner, Theodore J. Price
-
Patent number: 11306130Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 3 (PAR3) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR3 activity.Type: GrantFiled: March 31, 2017Date of Patent: April 19, 2022Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Josef Vagner, Scott A. Boitano, Theodore J. Price, Gregory O. Dussor
-
Patent number: 11230568Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: June 24, 2019Date of Patent: January 25, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNTVERSITY OF TEXAS SYSTEMInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Publication number: 20210230219Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: October 5, 2020Publication date: July 29, 2021Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20210107909Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to a new class of small-molecules having a pyrazino-pyrimidine-dione (or related) structure which function as modulators (activators, inhibitors) of protease activated receptor type 2 (PAR2), and their use as therapeutics for the treatment of conditions involving PAR2 activity (e.g., asthma, chronic pain, cancer and/or vascular disorders).Type: ApplicationFiled: April 9, 2019Publication date: April 15, 2021Inventors: Scott A. Boitano, Josef Vagner, Theodore J. Price, Gregory O. Dussor
-
Patent number: 10793595Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: October 3, 2018Date of Patent: October 6, 2020Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDAInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20200164093Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: ApplicationFiled: September 9, 2019Publication date: May 28, 2020Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of The University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20200002376Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: June 24, 2019Publication date: January 2, 2020Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
-
Publication number: 20190307426Abstract: A system and method that uses receptor-targeted microbubbles to locate abnormal cell tissue for therapy is disclosed. The method includes applying receptor-targeted microbubbles to abnormal cell tissue; imaging the applied microbubbles using an imaging system; and locating the abnormal cell tissue using the imaged, applied microbubbles, wherein the imaging system detects and 5 transmits imaging information of the applied microbubbles through a gaseous environment, i.e., a non-contact procedure. Embodiments of the system and method combine the targeting of microbubbles to abnormal cell tissue and an imaging system, the combination of which is capable of accurately and rapidly assessing the surgical margin for presence of unseen cancer in, for example, the operating room, at bedside, or in an 10 office, within or outside the body.Type: ApplicationFiled: July 7, 2017Publication date: October 10, 2019Inventors: Bhaskar Banerjee, Terry O. Matsunaga, Josef Vagner, Khanh Kieu
-
Patent number: 10406248Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 5, 2012Date of Patent: September 10, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board Of Regents on Behalf of the University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20190263857Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: October 3, 2018Publication date: August 29, 2019Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Patent number: 10329326Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: September 12, 2016Date of Patent: June 25, 2019Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC.Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 10308656Abstract: Provided herein are methods for identifying and treating subjects having conditions involving aberrant Ku70/80 activity. In particular, the invention relates to small-molecules which function as inhibitors of Ku70/80 protein and the non-homologous end-joining (NHEJ) pathway, and their use as therapeutics for the treatment of cancer and other diseases.Type: GrantFiled: August 16, 2016Date of Patent: June 4, 2019Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Eric Weterings, Daruka Mahadevan, Josef Vagner
-
Publication number: 20190117785Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.Type: ApplicationFiled: March 31, 2017Publication date: April 25, 2019Applicants: Arizona Board of Regents on Behalf of the University of Arizona, Board of Regents, The University of Texas SystemInventors: Scott A. BOITANO, Josef VAGNER, Theodore J. PRICE